Law Offices of Todd M. Garber Announces Investigation of Dynavax Technologies Corporation

DVAX

The Law Offices of Todd M. Garber announces that it is investigating potential claims against Dynavax Technologies Corporation (“Dynavax” or the “Company”) (NASDAQ:DVAX) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by Dynavax between April 26, 2012 and June 10, 2013 regarding the Company’s business and financial prospects.

Dynavax is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The investigation concerns allegations that that the Company issued false and misleading statements or failed to disclose material adverse facts concerning its biologic license application for Heplisav, an investigational adult hepatitis-B vaccine.

On June 10, 2013 the Company disclosed that in a meeting with the Food and Drug Administration (“FDA”) over its biologic license application for Heplisav, the FDA expressed that it wanted additional safety data from more patients before approving the drug. The FDA further expressed that analyzing Heplisav for smaller groups of patients did not fully address its concerns and that it would like to see additional safety trials. Moreover, as previously noted by the FDA, there are also ongoing concerns regarding Dynavax’s manufacturing and testing of Heplisav. Following this news, shares of Dynavax declined $1.07 per share, or 43.32%, to close on June 10, 2013, at $1.40 per share, on unusually heavy volume.

If you purchased Dynavax stock during the foregoing period, if you have information or would like to learn more about these claims, or if you purchased Dynavax shares prior to April 26, 2012 and wish to discuss these matters, please contact Todd M. Garber, Esquire, of the Law Offices of Todd M. Garber, by telephone at 213-700-7262 or by email to info@toddgarberlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Rate this press release
0 stars
v
Usefulness

Clarity

Credibility
Add to favourites icon Add to favourites

top
top